Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RORC | P51449 | 4/20 | 0.62 |
| ▸ | TACR1 | P25103 | 3/20 | 0.59 |
| ▸ | PDE4B | Q07343 | 5/20 | 0.58 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.47 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.47 |
| ▸ | NAMPT | P43490 | 1/20 | 0.45 |
| ▸ | USP7 | Q93009 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1254778 | 1.00 | RORC (0.62) | RORCTACR1PDE4BUSP30GPR119 | |
| SCHEMBL1751741 | 1.00 | RORC (0.62) | RORCTACR1PDE4BUSP30GPR119 | |
| SCHEMBL1254780 | 1.00 | RORC (0.62) | RORCTACR1PDE4BUSP30GPR119 | |
| SCHEMBL1751697 | 1.00 | RORC (0.62) | RORCTACR1PDE4BUSP30GPR119 | |
| SCHEMBL1254775 | 1.00 | RORC (0.62) | RORCTACR1PDE4BUSP30GPR119 | |
| SCHEMBL2738527 | 1.00 | RORC (0.62) | RORCTACR1PDE4BUSP30GPR119 | |
| SCHEMBL23021431 | 1.00 | RORC (0.62) | RORCTACR1PDE4BUSP30GPR119 | |
| SCHEMBL12380284 | 0.90 | RORC (0.61) | RORCTACR1PDE4BUSP30GPR119 | |
| SCHEMBL1972562 | 0.88 | PDE4B (0.58) | RORCTACR1PDE4BUSP30 | |
| SCHEMBL4004826 | 0.88 | PDE4B (0.58) | RORCTACR1PDE4BUSP30 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180169099-A1 | HYDROXYLATED AND METHOXYLATED PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2018-06-21 | — | — | US | disclosed |
| US-9717730-B2 | Combinations of AKT inhibitor compounds and chemotherapeutic agents, and methods of use | GENENTECH, INC. (US) | 2017-08-01 | — | — | US | disclosed |
| US-20170157124-A1 | COMBINATIONS OF AKT INHIBITOR COMPOUNDS AND CHEMOTHERAPEUTIC AGENTS, AND METHODS OF USE | GENENTECH, INC. (US) | 2017-06-08 | — | — | US | disclosed |
| US-9610289-B2 | Combinations of AKT inhibitor compounds and erlotinib, and methods of use | GENENTECH, INC. (US) | 2017-04-04 | — | — | US | disclosed |
| US-20160228440-A1 | COMBINATIONS OF AKT INHIBITOR COMPOUNDS AND CHEMOTHERAPEUTIC AGENTS, AND METHODS OF USE | GENENTECH, INC. (US) | 2016-08-11 | — | — | US | disclosed |
| US-9359340-B2 | Hydroxylated and methoxylated pyrimidyl cyclopentanes as Akt protein kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2016-06-07 | — | — | US | disclosed |
| US-20160152606-A9 | HYDROXYLATED AND METHOXYLATED PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS | GENENTECH, INC. | 2016-06-02 | — | — | US | disclosed |
| US-20160051550-A1 | COMBINATIONS OF AKT INHIBITOR COMPOUNDS AND ERLOTINIB, AND METHODS OF USE | GENENTECH, INC. (US) | 2016-02-25 | — | — | US | disclosed |
| US-9150548-B2 | Combinations of AKT inhibitor compounds and vemurafenib, and methods of use | GENENTECH, INC. (US) | 2015-10-06 | — | — | US | disclosed |
| US-9150549-B2 | Combinations of AKT inhibitor compounds and erlotinib, and methods of use | GENENTECH, INC. (US) | 2015-10-06 | — | — | US | disclosed |
| US-20140221386-A1 | COMBINATIONS OF AKT INHIBITOR COMPOUNDS AND ERLOTINIB, AND METHODS OF USE | GENENTECH, INC. (US) | 2014-08-07 | — | — | US | disclosed |
| US-20130065908-A1 | DIHYDROFURO PYRIMIDINES AS AKT PROTEIN KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2013-03-14 | — | — | US | disclosed |
| US-8329701-B2 | Dihydrofuro pyrimidines as AKT protein kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2012-12-11 | — | — | US | disclosed |
| US-20120232055-A1 | HYDROXYLATED AND METHOXYLATED PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS | GENENTECH, INC. (US) | 2012-09-13 | — | — | US | disclosed |
| US-8063050-B2 | Hydroxylated and methoxylated pyrimidyl cyclopentanes as AKT protein kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2011-11-22 | — | — | US | disclosed |
| US-20110269773-A1 | DIHYDROFURO PYRIMIDINES AS AKT PROTEIN KINASE INHIBITORS | ARRAY BIOPHARMA, INC. | 2011-11-03 | — | — | US | disclosed |
| US-20110245230-A1 | PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2011-10-06 | — | — | US | disclosed |
| US-8003651-B2 | Pyrimidyl cyclopentanes as AKT protein kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2011-08-23 | — | — | US | disclosed |
| US-20080058327-A1 | 4-piperazinyl-5H-6,7-dihydrocyclopenta(d)pyrimidines; Hyperproliferative diseases such as cancer | GENENTECH, INC. | 2008-03-06 | — | — | US | disclosed |
| US-20080051399-A1 | HYDROXYLATED AND METHOXYLATED PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS | ARRAY BIOPHARMA INC. | 2008-02-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170157124-A1 | COMBINATIONS OF AKT INHIBITOR COMPOUNDS AND CHEMOTHERAPEUTIC AGENTS, AND METHODS OF USE | AKT1, AKT2, MTOR | RORC 2670/4885TACR1 2449/4885PDE4B 1372/4885 |
| US-20080058327-A1 | 4-piperazinyl-5H-6,7-dihydrocyclopenta(d)pyrimidines; Hyperproliferative diseases such as cancer | PIK3CA, DPYD, CDK2 | RORC 619/4885TACR1 4048/4885PDE4B 1395/4885 |
| US-20130065908-A1 | DIHYDROFURO PYRIMIDINES AS AKT PROTEIN KINASE INHIBITORS | DPYD, DTYMK, PIK3CA | RORC 1265/4885TACR1 4228/4885PDE4B 1954/4885 |
| US-20160228440-A1 | COMBINATIONS OF AKT INHIBITOR COMPOUNDS AND CHEMOTHERAPEUTIC AGENTS, AND METHODS OF USE | AKT1, AKT2, MTOR | RORC 2670/4885TACR1 2449/4885PDE4B 1372/4885 |
| US-20080051399-A1 | HYDROXYLATED AND METHOXYLATED PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS | AKT1, AKT2, AKT1S1 | RORC 858/4885TACR1 3078/4885PDE4B 1708/4885 |
| US-20110269773-A1 | DIHYDROFURO PYRIMIDINES AS AKT PROTEIN KINASE INHIBITORS | DPYD, PIK3CA, DTYMK | RORC 1351/4885TACR1 4186/4885PDE4B 1934/4885 |
| US-20160051550-A1 | COMBINATIONS OF AKT INHIBITOR COMPOUNDS AND ERLOTINIB, AND METHODS OF USE | AKT1, AKT2, MTOR | RORC 3062/4885TACR1 2570/4885PDE4B 2169/4885 |
| US-20180169099-A1 | HYDROXYLATED AND METHOXYLATED PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS | AKT1, AKT2, AKT1S1 | RORC 858/4885TACR1 3078/4885PDE4B 1708/4885 |
| US-20160152606-A9 | HYDROXYLATED AND METHOXYLATED PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS | AKT1, AKT2, AKT1S1 | RORC 858/4885TACR1 3078/4885PDE4B 1708/4885 |
| US-20120232055-A1 | HYDROXYLATED AND METHOXYLATED PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS | AKT1, AKT2, AKT1S1 | RORC 858/4885TACR1 3078/4885PDE4B 1708/4885 |
| US-20140221386-A1 | COMBINATIONS OF AKT INHIBITOR COMPOUNDS AND ERLOTINIB, AND METHODS OF USE | AKT1, AKT2, MTOR | RORC 2842/4885TACR1 2644/4885PDE4B 2083/4885 |
| US-20110245230-A1 | PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS | TK1, PIK3CA, AKT1 | RORC 923/4885TACR1 2284/4885PDE4B 1462/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.